MiniMed Group, Inc. (MMED)
NASDAQHealth CareMedical - Equipment & ServicesSnapshot 2026-11-05
$18.16-5.86%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Equipment & ServicesSnapshot 2026-11-05
QuarterlyIQ Insights · MMED
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -66.7% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 10.7% |
Growth built into the price is above our model estimate.
The price assumes 77.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 0 industry peers · Company calendar date is not available
MMED — M&A activity — Changes in Control of Registrant
Dated 2026-10-16
Changes in Control of Registrant. On October 15, 2026, the previously announced exchange offer (the “Exchange Offer”) of up to an aggregate of 252,813,348 newly issued shares of common stock of MiniMed Group, Inc. (“MiniMed” or the “Company”) in exchange for outstanding ordinary shares of Medtronic plc (“Medtronic”) was completed. The Exchange Offer is described in a registration statement on Form S-4 (File No. 333-298914) originally filed by MiniMed with the Securities and Exchange Commissio…
Why it matters: MiniMed raised its FY27 growth outlook after a strong first quarter. Falling short would weaken the growth case.
Worry ifFY27 organic revenue growth is below the 10.5% outlook, despite the stated benefit from an extra week.
Less concerning ifFY27 organic revenue growth reaches or exceeds 10.5%.
Why it matters: MiniMed said Flex and new sensor launches drove U.S. new pump sales above 20% growth. A slowdown would test that launch boost.
Worry ifU.S. New Pumps Sold growth falls below 20% year over year in a reported quarter.
Less concerning ifU.S. New Pumps Sold growth stays at or above 20% year over year.
Why it matters: MiniMed set a November launch after winning the CE Mark. Sales would show whether the new pump can add patients outside the U.S.
Supportive ifMiniMed confirms the November launch and reports new Flex users or pump sales in Europe.
Worry ifThe launch slips past November, or MiniMed reports no new European users or sales.
Why it matters: The FDA submission is a key step toward the planned U.S. launch. A delay could push back access to the patch pump.
Watch forThe FDA clears MiniMed Fit in time for the planned Summer 2027 U.S. launch.
Also watch forThe FDA rejects the filing or review delays put the Summer 2027 launch at risk.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$224 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $559 loss on $10,000 · 5.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,159 loss on $10,000 · 41.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Vivera is a fully closed-loop system for people with type 1 and type 2 diabetes. Trial results will test the planned launch path.
Watch forMiniMed reports that the U.S. pivotal trial met its main goal and keeps the second-half 2027 launch plan.
Also watch forThe trial misses its main goal or MiniMed pushes the U.S. launch past the second half of 2027.